Epidemiology of Posttransplant Lymphoproliferative Disorders in Adult Kidney and Kidney Pancreas Recipients: Report of the French Registry and Analysis of Subgroups of Lymphomas

Caillard, Sophie; Lamy, François-Xavier; Quelen, Céline; Dantal, Jacques; Lebranchu, Yvon; Lang, Ph.; Velten, Michel; Moulin, Anne‐Marie

doi:10.1111/j.1600-6143.2011.03896.x

Cited by 175 publications

(194 citation statements)

References 36 publications

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…Several studies have found an association between posttransplantation cancer risk and receipt of induction therapy with lymphocyte depleting antibodies or maintenance immunosuppression with specific agents (10,(26)(27)(28)(29)(30). There are no published data directly comparing the dose and type of immunosuppressive agents for liver, heart and lung transplant recipients in Australia.…”

Section: Discussionmentioning

confidence: 99%

Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients

Grulich

Meagher

et al. 2013

American Journal of Transplantation

View full text Add to dashboard Cite

Population-based evidence on the relative risk of de novo cancer in liver and cardiothoracic transplant recipients is limited. A cohort study was conducted in Australia using population-based liver (n = 1926) and cardiothoracic (n = 2718) registries (1984-2006). Standardized incidence ratios (SIRs) were computed by cancer type, transplanted organ and recipient age. Cox regression models were used to compare cancer incidence by transplanted organ. During a median 5-year follow-up, the risk of any cancer in liver and cardiothoracic recipients was significantly elevated compared to the general population (n = 499; SIR = 2.62, 95%CI 2.40-2.86). An excess risk was observed for 16 cancer types, predominantly cancers with a viral etiology. The pattern of risk by cancer type was broadly similar for heart, lung and liver recipients, except for Merkel cell carcinoma (cardiothoracic only). Seventeen cancers (10 non-Hodgkin lymphomas), were observed in 415 pediatric recipients (SIR = 23.8, 95%CI 13.8-38.0). The adjusted hazard ratio for any cancer in all recipients was higher in heart compared to liver (1.29, 95%CI 1.03-1.63) and lung compared to liver (1.65, 95%CI 1.26-2.16). Understanding the factors responsible for the higher cancer incidence in cardiothoracic compared to liver recipients has the potential to lead to targeted cancer prevention strategies in this high-risk population.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients

Grulich

Meagher

et al. 2013

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Ancak Avustralya-Yeni Zellanda Diyaliz ve Nakil Cemiyeti'nin analizlerine göre bifazik görülme paterni olabileceği ileri sürülmektedir. Nakilden 7-10 yıl sonra ikinci bir pik gözlenmiştir (33) . İlk 12 ay içinde belirlenirse "erken", 12 ay sonrası "geç" PTLD olarak, isimlendirilmektedir.…”

Section: Epstein-barr Virusunclassified

Pediatric Solid Organ Transplant Infections

Törün¹,

Acar²,

Salman³

et al. 2016

Cocuk Dergisi

View full text Add to dashboard Cite

“…El riesgo de presentación es de 10 a 20 veces más alto que en la población general 1,2 . Afecta de 1 a 20 % de pacientes con TOS 2,3 .…”

unclassified

“…El riesgo de presentación es de 10 a 20 veces más alto que en la población general 1,2 . Afecta de 1 a 20 % de pacientes con TOS 2,3 . La incidencia es de 0,7 % a 2,9 % en el trasplante renal 1,3 , siendo mayor en trasplante de intestino, páncreas y pulmón (4-7 %) 1,3 .…”

unclassified

“…Se caracteriza por la producción descontrolada de linfocitos B y de linfocitos T, con menos frecuencia 3,4 . Existen factores de riesgo asociados, como raza caucásica, infección primaria por el virus Epstein Barr (EBV), uso de anticuerpos antilinfocíticos en terapia de inducción, coinfección por citomegalovirus (CMV), terapia antiviral, rechazo del injerto y tiempo previo en diálisis 2,5 . PTLD durante el primer año de trasplante, o de presentación temprana, es la forma más frecuente (hasta un 40 %) y puede asociarse a CD20 positivo.…”

unclassified

See 1 more Smart Citation

Enfermedad linfoproliferativa en el injerto renal. Reporte de un caso y revisión de la literatura

Sánchez

Padilla

Contreras

et al. 2017

Rev. Colomb. Nefrol.

View full text Add to dashboard Cite

Referenciar este artículo: Rodríguez Sánchez MP, García Padilla PK, Contreras KM, González González CA, Puentes S. Enfermedad linfoproliferativa en el injerto renal. Informe de un caso y revisión de la literatura Rev. Colomb. Nefrol. 2017;4(2) ResumenLos desórdenes linfoproliferativos postrasplante (PTLD por sus siglas en inglés: Posttransplant Lymphoproliferative disorders) se presentan en 3 a 10% de adultos con trasplante de órgano sólido (TOS). Se ha asociado a infección por Virus Epstein Barr (VEB). Es difícil diferenciar PTLD de rechazo o infección viral, porque los hallazgos clínicos e histopatológicos son muy similares. Presentamos el caso de un paciente con enfermedad renal crónica (ERC) secundaria a glomerulonefritis IgM, con trasplante renal de donante cadavérico, quien presentó proteinuria y disminucuón de la función renal, se le documentó una masa en el injerto renal compatible con desorden linfoproliferativo postrasplante renal de tipo polimórfico (PTLD), VEB positivo y CD 20 positivo. El tratamiento consistió en rituximab 375 mg/m2 semanales, cuatro dosis, se realizó control con imágenes y se adicionó el esquema CHOP (ciclofosfamida, vincristina, doxorubicina). El paciente toleró de manera adecuada la quimioterapia, no requirió radioterapia, ni trasplantectomía y después del R-CHOP la masa disminuyó de manera significativa hasta desaparecer al año de seguimiento manteniendo función óptima del injerto renal. .218Abstract Posttransplant Lymphoproliferative Disorders (PTLDs) occur in 3 to 10% of adults with solid organ transplant (SOT). It has been associated with Epstein Barr Virus (EBV) infection. Differential diagnostics of PTLD from rejection or viral infection is difficult when the tumor infiltrates the graft, because the clinical and histopathological findings are similar. We report a case of patient with chronic kidney disease due to Ig M glomerulonephritis with cadaveric donor kidney transplantation who presented proteinuria and decreased glomerular filtration rate, with a solid mass at renal graft and confirmatory histology of polymorphic renal transplant lymphoproliferative disorder (PTLD), VEB positive, and CD 20 positive. The patient was treated with rituximab 375 mg / m2 weekly, four doses, followed by chemotherapy with ciclophosphamide, vincristine and doxorubicin. He didn't need radiotherapy or graft nephrectomy, with complete remission at one year of follow-up and optimal graft function.

show abstract

Epidemiology of Posttransplant Lymphoproliferative Disorders in Adult Kidney and Kidney Pancreas Recipients: Report of the French Registry and Analysis of Subgroups of Lymphomas

Cited by 175 publications

References 36 publications

Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients

Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients

Pediatric Solid Organ Transplant Infections

Enfermedad linfoproliferativa en el injerto renal. Reporte de un caso y revisión de la literatura

Contact Info

Product

Resources

About